;
Skip to main content
Home > SciBX > Cover Story

Chronological Index of : Cover Story

 Current Issue
  • Figure 1: Putting the brakes or gas on T cell function

    Cover Story: Putting on the brakes Figure 1. Putting the brakes or gas on T cell function. Inhibitory chimeric antigen receptors (iCARs) put the brakes on T cell function upon encountering off-target cells. The iCAR …

    Published on 1/16/2014
  • Light it up

    Poor tumor definition makes it hard to remove all malignant cells during cancer surgery. A Texas team has designed fluorescent nanoparticles that can light up tumors regardless of genotype or phenotype, potentially …

    Published on 1/9/2014
  • Figure 1: Ultra pH-sensitive (UPS) nanoprobes shed new light on tumors

    Cover Story: Light it up Figure 1. Ultra pH-sensitive (UPS) nanoprobes shed new light on tumors. The UPS nanoprobes stay 'off' at pH 7.4 in normal blood vasculature. After reaching tumors, the UPS nanoprobes are …

    Published on 1/9/2014
  • Oral nanoparticles

    A U.S. research team has developed targeted nanoparticles that could enable the oral delivery of biologics. Translation of the approach will require identifying a suitable therapeutic payload and fine-tuning the …

    Published on 12/19/2013
  • T cells go universal

    Scientists have engineered T cells that engage in antibody-dependent cellular cytotoxicity and enhance the antitumor potential of any immunotherapeutic antibody. The team plans to test the T cell and antibody …

    Published on 12/12/2013
  • Targeting fibrotic integrin

    An international team of researchers has shown that the myofibroblast-expressed integrin alpha(V) subunit drives fibrosis and that a small molecule integrin alpha(V) antagonist from Antegrin Therapeutics can attenuate …

    Published on 12/5/2013
  • Glucokinase alternative

    Compounds that directly activate glucokinase effectively reduce blood sugar in patients with diabetes but increase the risk of adverse hypoglycemic events. Now, researchers from Amgen have identified compounds that act …

    Published on 11/21/2013
  • Table 1: Glucokinase activators in clinical development

    Cover Story: Glucokinase alternative Table 1. Glucokinase activators in clinical development. Despite the discontinuation of some programs from large pharmas, including Merck & Co. Inc. (NYSE:MRK), Takeda …

    Published on 11/21/2013
  • Trends with benefits

    The FDA set up its adverse event database to capture the side effects of marketed drugs, but U.S. researchers have now exploited the resource to extract new information-beneficial combinations that reduce a drug's risk …

    Published on 11/14/2013
  • ALS antisense oligonucleotides

    Isis and three academic groups are developing antisense oligonucleotide therapeutics for the most common cause of ALS. The drugs target hexanucleotide repeat expansions in C9orf72 and mitigate neurotoxicity in vitro. …

    Published on 11/7/2013
  • Figure 1: Meditope-enabled mAbs

    Cover Story: Building meditope-enabled mAbs Figure 1. Meditope-enabled mAbs. As reported by Donaldson et al., the Fab framework of the chimeric anti-epidermal growth factor receptor (EGFR) mAb Erbitux cetuximab …

    Published on 10/31/2013
  • Building meditope-enabled mAbs

    Researchers at the Beckman Research Institute at City of Hope have provided proof of concept for adapting the functionality of mAbs by modifying them with engineered peptides called meditopes. The institute founded …

    Published on 10/31/2013
  • Figure 1: Drug-like chemical modifications to nucleic acids

    A platform for RNA Figure 1. Drug-like chemical modifications to nucleic acids. Nucleic acids are not drug-like molecules, and chemical modifications are required to improve their pharmacokinetic and other properties…

    Published on 10/24/2013
  • Figure 2: The RNAi pathway

    A platform for RNA Figure 2. The RNAi pathway. MicroRNAs are transcribed in the nucleus as precursor pri-miRNAs, which form hairpins that are processed to mature miRNAs by two RNase III enzymes, drosha and dicer. [a(…

    Published on 10/24/2013
  • Table 1: Oligonucleotide therapeutic companies

    A platform for RNA Table 1. Oligonucleotide therapeutic companies. Source: BCIQ: BioCentury Online Intelligence; company press releases and websites Company Modality Stage of lead compound Antisense Therapeutics …

    Published on 10/24/2013
  • Table 2: Recent deals

    A platform for RNA Table 2. Recent deals. Deals between Isis Pharmaceuticals Inc. and Biogen Idec Inc., and Moderna Therapeutics Inc. and AstraZeneca plc, highlight increasing investments in oligonucleotide-based …

    Published on 10/24/2013
  • Table 3: Oligonucleotide toolkits

    A platform for RNA Table 3. Oligonucleotide toolkits. Through a host of partnerships, many pharmas now have the ability to target multiple types of RNAs using multiple modalities. Company Antisense Small …

    Published on 10/24/2013
  • A platform for RNA

    An information explosion on the numbers and mechanisms of functional RNAs has spurred oligonucleotide-based therapeutic development. Pharmas and big biotechs are carving up the space via partnerships, adding multiple …

    Published on 10/24/2013
  • Revving up cGAS

    University of Texas Southwestern Medical Center researchers have confirmed the role of cyclic GMP-AMP signaling in the innate immune system, making a case for developing adjuvants that agonize the pathway or antagonists…

    Published on 10/17/2013
  • Figure 1: Cyclic GMP-AMP signaling in the immune response

    Revving up cGAS Figure 1. Cyclic GMP-AMP signaling in the immune response. Although cytosolic DNA (a) has long been known to trigger an immune response, it was only this year that its primary molecular sensor was …

    Published on 10/17/2013
  • NSD2 momentum

    NSD2 has been genetically linked to multiple myeloma for years, but drug discovery efforts against the target have floundered. Two teams provide compelling evidence that inhibiting the protein could help treat …

    Published on 10/10/2013
  • Escaping abiraterone

    Although a lot is known about how castration-resistant prostate cancers become refractory to second-generation androgen receptor antagonists, the mechanism behind resistance to CYP17 inhibitors remains a mystery. An …

    Published on 10/3/2013
  • Figure 1: Androgen synthesis pathways in prostate cancer

    Cover Story: Escaping abiraterone Figure 1. Androgen synthesis pathways in prostate cancer. In testicular androgen synthesis­, luteinizing hormone-releasing hormone (LHRH) stimulates release of luteinizing hormone (…

    Published on 10/3/2013
  • Table 1: Table 1. CD20: A new angle of attack

    Cover Story: Anti-CD20 therapy for heart attack Table 1. CD20: A new angle of attack. A study by a multinational team suggests that depleting B cells with anti-CD20 therapy shortly after myocardial infarction (MI) …

    Published on 9/26/2013
  • Anti-CD20 therapy for heart attack

    A multinational team has used anti-CD20 mAbs to treat heart attacks by depleting inflammation-causing CD20+ B cells at the infarct site. The researchers are planning a Phase IIa trial of Rituxan in MI, and at least one …

    Published on 9/26/2013

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993